American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Xenon Pharmaceuticals Inc. (XENE)

$42.10 +1.72% NASDAQ: XENE · 15-min delayed

BURNABY,
Public · NASDAQ: XENE
370 employees

Visit website Follow

$6.3BMarket cap

$311.0KRevenue · FY2017

-$345.9MNet income

370Employees

XENENASDAQ

2014IPO

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: XENE
Employees: 370
IPO date: Nov 5, 2014
Headquarters: 200 - 3650 GILMORE WAY
BURNABY,
Phone: (604) 484-3300
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: CA — outside the United States
Registered office: Vancouver, CA
Legal entity ID: 549300XV44Q9Z1MIPQ03

Source: GLEIF, the global Legal Entity Identifier registry · checked Aug 8, 2026. A US headquarters does not always mean US incorporation.

Is Xenon Pharmaceuticals Inc. an American company? No. Xenon Pharmaceuticals Inc. is incorporated in Canada. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Registry IDs

Ticker: XENE Nasdaq
SEC CIK: 1582313
LEI: 549300XV44Q9Z1MIPQ03
EIN: 980661854
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Xenon Pharmaceuticals Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/xenon-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/xenon-pharmaceuticals-inc.svg" alt="Xenon Pharmaceuticals Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Xenon Pharmaceuticals Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2017: $311.0K
Net income: -$345.9M
Total assets: $633.2M
Market cap: $6.3B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: XENE

$42.10 +1.72%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$33.49 $70.96

52-week range

Market cap: $6.3B
Shares outstanding: 150.2M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 5, 2014

Xenon Pharmaceuticals Inc. (XENE) Stock Price

Reported a net loss of $345.9M in FY2017.
Trading 41% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Xenon Pharmaceuticals Inc..

Write a review

Newsroom

News about Xenon Pharmaceuticals Inc.

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors GlobeNewswire Inc. · 2026-10-21 · negative XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? Zacks Investment Research · 2026-10-15 · negative XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback Zacks Investment Research · 2026-09-18 · mixed Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight GlobeNewswire Inc. · 2026-06-10 · positive Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting GlobeNewswire Inc. · 2026-04-19 · positive Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know The Motley Fool · 2026-03-27 · positive

News & sentiment via Polygon.io

FAQ

Xenon Pharmaceuticals Inc.: frequently asked questions

Is Xenon Pharmaceuticals Inc. an American company?

No — Xenon Pharmaceuticals Inc. is not an American company. Xenon Pharmaceuticals Inc. is incorporated in Canada. It maintains US operations and its shares trade on NASDAQ — which is why it is often mistaken for a US company.

Where is Xenon Pharmaceuticals Inc. incorporated?

Xenon Pharmaceuticals Inc. is legally incorporated in Canada, according to its GLEIF legal-entity record.

Is Xenon Pharmaceuticals Inc. traded on a US stock exchange?

Yes — Xenon Pharmaceuticals Inc. trades under the ticker XENE on the NASDAQ. A US stock listing does not by itself make a company American — incorporation and ownership are what this page reports.

Is Xenon Pharmaceuticals Inc. publicly traded?

Yes — Xenon Pharmaceuticals Inc. is a publicly traded company. Its stock trades under the ticker symbol XENE on the NASDAQ.

What does Xenon Pharmaceuticals Inc. do?

Xenon Pharmaceuticals Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore